Roche/Exelixis' Cotellic fizzles in pivotal melanoma study

Roche/Exelixis' Cotellic fizzles in pivotal melanoma study

Source: 
Endpoints
snippet: 

To little surprise, Exelixis’ Cotellic — known chemically as cobimetinib — in combination with Roche’s Tecentriq, has failed a late-stage study as a frontline treatment for patients with a form of advanced melanoma.